Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I clinical trial of MVA-based recombinant vaccine (MVA-MERS-S) encoding Middle East Respiratory Syndrome coronavirus spike protein

Proposed period of release:
01/01/2017 to 30/09/2017

Name of the Institute(s) or Company(ies)
Universitätsklinikum Hamburg-Eppendorf (UKE), ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Recombinant Modified Vaccinia Virus Ankara (MVA) delivering the S-glycoprotein of the Middle East Respiratory Syndrome (MERS) coronavirus, MVA-MERS-S (Song et al., 2013).
Genus: Orthopoxvirus
Species: Vaccinia virus

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
MVAOrthopoxvirusvaccinia virus-Modified vaccinia virus Ankara-

European Commission administrative information

Consent given by the Member State Competent Authority:
22/11/2018 00:00:00